

26 July 2024
EMA/245297/2013 Rev. 124*
Human Medicines Division

List of medicinal products under additional monitoring

Related Information:

[Additional monitoring explained:](https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring)

<https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring>

[Good Pharmacovigilance Practice Module on additional monitoring:](https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices)

<https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

For the UK, as from 1st January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI

To note: All products added to the list in July 2024 are shown in red font. All products removed from the list are shown with a strikethrough for the period of one month after which they are excluded. For products newly added to the list, EMA will update the 'Product details' section of the medicine page on EMA's corporate website when it publishes the revised summary of product characteristics.

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Abevmy	bevacizumab	New biological	Biosimilar Collaborations Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/abevmy-epar-product-information_en.pdf	May/21
Abecma	idecabtagene vicleucel respiratory syncytial virus vaccine (bivalent, recombinant)	New biological, new active substance, PASS ¹	Bristol-Myers Squibb Pharma EEIG	https://www.ema.europa.eu/en/documents/product-information/abecma-epar-product-information_en.pdf	September 2021
Abrysvo		New active substance and new biological	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/abrysvo-epar-product-information_en.pdf	September 2023
Adynovi	Rurioctocog alfa pegol	PASS ¹	Baxalta Innovations GmbH	https://www.ema.europa.eu/en/documents/product-information/adynovi-epar-product-information_en.pdf	January 2018
Adtralza	tralokinumab	New active substance and <i>new biological</i>	Leo Pharma A/S	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?accessid=amis_off_am_ppv&directdisplay=true&mpdid=...	June 2021
Afluria Tetra	Influenza vaccine (split virion, inactivated)	New biological	Seqirus Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/agamree-epar-product-information_en.pdf	September 2020
AGAMREE	vamorolone	New active substance	Santhera Pharmaceuticals (Deutschland) GmbH	http://mri.cts-mrp.eu/Human/Product/Details/58971	January 2024
Aklief	trifarotene	New active substance	Galderma Nordic AB	https://www.ema.europa.eu/en/documents/product-information/altuvoct-epar-product-information_en.pdf	December 2021
ALTUVOCT	efanesoctocog alfa	New active substance and new biological	Swedish Orphan Biovitrum AB (publ)	https://www.ema.europa.eu/en/documents/product-information/alymsys-epar-product-information_en.pdf	June 2024
Alymsys	bevacizumab	New biological	Mabxience Research SL		April 2021

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Amsparity	Adalimumab	New biological	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf	February 2020
Amvuttra	vutrisiran	New active substance	Alnylam Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/amvuttra-epar-product-information_en.pdf	September 2022
Anoro Ellipta	Umeclidinium bromide/vilanterol trifenate pneumococcal polysaccharide conjugate vaccine (20-valent,	PASS ¹	GlaxoSmithKline (Ireland) Limited	https://www.ema.europa.eu/en/documents/product-information/anoro-ellipta-epar-product-information_en.pdf	June 2014
Apexxnar		New biological	☐ Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/apexxnar-epar-product-information_en.pdf	March 2022
Apretude	cabotegravir	New active substance	ViiV Healthcare BV	https://www.ema.europa.eu/en/documents/product-information/apretude-epar-product-information_en.pdf	September 2023
AQUIPTA	Etiogepant	New active substance	AbbVie Deutschland GmbH & Co. KG	https://www.ema.europa.eu/en/documents/product-information/aquipta-epar-product-information_en.pdf	September 2023
Arexvy	Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)	New active substance and new biological	GlaxoSmithKline Biologicals S.A.	https://www.ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_en.pdf	June 2023
Artesunate Amivas	artesunate	New active substance	Amivas Ireland Ltd	https://www.ema.europa.eu/en/documents/product-information/artesunate-amivas-epar-product-information_en.pdf	Dec/21
Aspaveli	pegcetacoplan	New active substance	☐ Swedish Orphan Biovitrum AB (publ)	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?accessid=amis_off_am_ppv&directdisplay=true&mpdid=...	January 2022
Atgam	anti-human T-lymphocyte immunoglobulin	New biological	Pfizer Pharma GmbH	https://www.ema.europa.eu/en/documents/product-information/atgam-epar-product-information_en.pdf	March 2022
Atriance	Nelarabine	Authorised under exceptional circumstances	Sandoz Pharmaceuticals d.d.	https://www.ema.europa.eu/en/documents/product-information/atriance-epar-product-information_en.pdf	April 2013
Awikli	insulin icodec	New active substance, New biological	Novo Nordisk A/S	https://www.ema.europa.eu/en/documents/product-information/awikli-epar-product-information_en.pdf	May 2024
Aybintio	bevacizumab	New biological	Samsung Bioepis NL B.V.	https://www.ema.europa.eu/en/documents/product-information/aybintio-epar-product-information_en.pdf	August 2020
AYVAKYT	avapritinib	New active substance, conditional marketing authorisation	Blueprint Medicines (Netherlands) B.V.	https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf	September 2020
Bavencio	Avelumab	New active substance and <i>new biological</i> ,	Merck Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/bavencio-epar-product-information_en.pdf	September 2017
BEKEMV	eculizumab	New biological	Amgen Technology (Ireland) UC	https://www.ema.europa.eu/en/documents/product-information/bekemv-epar-product-information_en.pdf	April 2023
Benlysta	Belimumab	PASS ¹	Glaxo Group Ltd	https://www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf	April 2013
Beovu	Brolucizumab	New active substance and <i>new biological</i>	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/beovu-epar-product-information_en.pdf	February 2020
Beyfortus	Ertsevimev	New active substance and <i>new biological</i>	Sanofi Winthrop Industrie	https://www.ema.europa.eu/en/documents/product-information/beyfortus-epar-product-information_en.pdf	November 2022
BIMERVAX	COVID-19 Vaccine (recombinant, adjuvanted)	New active substance and new biological	Eipra Human Health, S.L.U.	https://www.ema.europa.eu/en/documents/product-information/bimervax-epar-product-information_en.pdf	April 2023

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Bimzelx	bimekizumab	New active substance and new biological	UCB Pharma S.A.	https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf	September 2021
Blinicyto	Blinatumomab	PASS ¹	Amgen Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf	December 2015
Bylvay	Odevixibat	New active substance, authorised under exceptional circumstances	Ipsen Pharma	https://www.ema.europa.eu/en/documents/product-information/bylvay-epar-product-information_en.pdf	July 2021
Byooviz	ranibizumab	New biological	Samsung Bioepis NL B.V.	https://www.ema.europa.eu/en/documents/product-information/byooviz-epar-product-information_en.pdf	April 2024
Bretaris Genuair	Acridinium bromide	PASS ¹	AstraZeneca AB	https://www.ema.europa.eu/en/documents/product-information/bretaris-genuair-epar-product-information_en.pdf	April 2013
Breyanzi	lisocabtagene maraleucel	New biological, new active substance, PASS ¹	Bristol Myers Squibb Pharma EEIG	https://www.ema.europa.eu/en/documents/product-information/breyanzi-epar-product-information_en.pdf	April 2022
Brimica Genuair	Acridinium bromide/formoterol fumarate dihydrate	PASS ¹	Covis Pharma Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/brimica-genuair-epar-product-information_en.pdf	December 2014
Brineura	Cerliponase alfa	authorised under exceptional circumstances, PASS ¹	BioMarin International Limited	https://www.ema.europa.eu/en/documents/product-information/brineura-epar-product-information_en.pdf	June 2017
Briumvi	Ublituximab	New active substance and new biological	Neuraxpharm Pharmaceuticals, S.L.	https://www.ema.europa.eu/en/documents/product-information/briumvi-epar-product-information_en.pdf	June 2023
Brukinsa	zanubrutinib	New active substance	BeiGene Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information_en.pdf	December 2021
Byfavo	remimazolam	New active substance	PAION Deutschland GmbH	https://www.ema.europa.eu/en/documents/product-information/byfavo-epar-product-information_en.pdf	April 2021
Calquence	acalabrutinib	New active substance	AstraZeneca AB	https://www.ema.europa.eu/en/documents/product-information/calquence-epar-product-information_en.pdf	November 2020
CAMZYOS	mavacamten	New active substance	Bristol Myers Squibb Pharma EEIG	https://www.ema.europa.eu/en/documents/product-information/camzyos-epar-product-information_en.pdf	July 2023
CARVYKTI	ciltacabtagene autoleucel	New active substance, new biological	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/carvykti-epar-product-information_en.pdf	June 2022
Casgevya	Eragalinolone autotemcel	New active substance, new biological and conditional marketing authorisation, PASS	Vertex Pharmaceuticals (Ireland) Limited	https://www.ema.europa.eu/en/documents/product-information/casgevya-epar-product-information_en.pdf	February 2024
Cejemly	sugemalimab	New active substance and new biological	SFL Pharmaceuticals Deutschland GmbH	Not available yet	July 2024
Celldemic	Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated,	New biological	Seqirus Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/celldemic-epar-product-information_en.pdf	May 2024
Cefila (previously Pegfilgrastim Mundipharma)	Pegfilgrastim	New biological	Mundipharma Corporation (Ireland) Limited	https://www.ema.europa.eu/en/documents/product-information/cefila-epar-product-information_en.pdf	January 2020
Ceplene	Histamine dihydrochloride	Authorised under exceptional circumstances	Laboratoires Delbert	https://www.ema.europa.eu/en/documents/product-information/ceplene-epar-product-information_en.pdf	April 2013
Cerdelga	Eliglustat	PASS ¹	Genzyme Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/cerdelga-epar-product-information_en.pdf	February 2015

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Cevenfacta Chenodeoxycholic acid	eptacog beta (activated)	New active substance and new biological	Laboratoire français du Fractionnement et des Biotechnologies	https://www.ema.europa.eu/en/documents/product-information/cevenfacta-epar-product-information_en.pdf	September 2022
Leadiant (previously known as)	Chenodeoxycholic acid	Authorised under exceptional circumstances	Leadiant GmbH	https://www.ema.europa.eu/en/documents/product-information/cerdelga-epar-product-information_en.pdf	April 2017
Choriongonadotrophin Genevrier	chorionic gonadotropin	New biological	Laboratoires Génévrier	N/A	January 2022
Cibinqo Cidofovir 75 mg/ml Concentrate for Solution for Infusion	abrocitinib	New active substance	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/cibinqo-epar-product-information_en.pdf	January 2022
	Cidofovir	PASS ¹	Emcure Pharma UK Limited	http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1466141046287.pdf	May 2016
Cinryze	c1 inhibitor, human	PASS ¹	Takeda Manufacturing Austria AG	https://www.ema.europa.eu/en/documents/product-information/cinryze-epar-product-information_en.pdf	April 2013
				N/A	
Colevance	enoxaparin sodium	New biological	Venipharm		January 2022
Columvi	glofitamab	New active substance, new biological and conditional marketing authorisation	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/columvi-epar-product-information_en.pdf	July 2023
Comirnaty	COVID-19 mRNA Vaccine (nucleoside modified)	New active substance and new biological	BioNTech Manufacturing GmbH	https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf	Jan/21
Copiktra	duvelisib	New active substance	Secura Bio Limited	https://www.ema.europa.eu/en/documents/product-information/copiktra-epar-product-information_en.pdf	Jun/21
				Not available	
Crusia	Enoxaparin sodium	New biological	Laboratorios Farmacéuticos Rovi S.A.	https://www.ema.europa.eu/en/documents/product-information/daurismo-epar-product-information_en.pdf	May 2024
Daurismo	Glasdegib	New active substance	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/dectova-epar-product-information_en.pdf	July 2020
Dectova	Zanamivir	Authorised under exceptional circumstances	GlaxoSmithKline Trading Services Limited	https://www.ema.europa.eu/en/documents/product-information/dectova-epar-product-information_en.pdf	May 2019
Defitelio	Defibrotide	Authorised under exceptional circumstances	Gentium S.p.A.	https://www.ema.europa.eu/en/documents/product-information/defitelio-epar-product-information_en.pdf	November 2013
Deltyba	Delamanid Aclidinium bromide/formoterol fumarate dihydrate	Conditional authorisation	Otsuka Novel Products GmbH	https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-information_en.pdf	May 2014
Duaklir Genuair		PASS ¹	Covis Pharma Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/duaklir-genuair-epar-product-information_en.pdf	December 2014
Drovelis	drosiprenone/estetrol	New active substance	Gedeon Richter Plc.	https://www.ema.europa.eu/en/documents/product-information/drovelis-epar-product-information_en.pdf	June 2021
Ebglyss	lebrikizumab	New active substance, new biological	Almirall S.A.	https://www.ema.europa.eu/en/documents/product-information/ebglyss-epar-product-information_en.pdf	November 2023
Ebvallo	Tabelecleucel	New active substance and new biological, Authorised under exceptional circumstances	Pierre Fabre Medicament	https://www.ema.europa.eu/en/documents/product-information/ebvallo-epar-product-information_en.pdf	January 2023
Eklira Genuair	Aclidinium bromide	PASS ¹	Covis Pharma Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/eklira-genuair-epar-product-information_en.pdf	April 2013
Eladynos	abaloparatide	New active substance	Theramex Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/eladynos-epar-product-information_en.pdf	January 2023

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Elaprase	Idursulfase	Authorised under exceptional circumstances	Takeda Pharmaceuticals International AG Ireland Branch	https://www.ema.europa.eu/en/documents/product-information/elaprase-epar-product-information_en.pdf	April 2013
Elfabrio	pegunigalsidase alfa	New active substance and new biological	Chiesi Farmaceutici S.p.A.	https://www.ema.europa.eu/en/documents/product-information/elfabrio-epar-product-information_en.pdf	May 2023
□ Elucirem	gadopiclenol	New active substance	Guerbet	https://www.ema.europa.eu/en/documents/product-information/elucirem-epar-product-information_en.pdf	January 2024
ELREXFIO	elranatamab Quadrivalent Influenza Vaccine (Split Virion, Inactivated)	New biological, new active substance, conditional marketing authorisation	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/elrefxio-epar-product-information_en.pdf https://cima.aemps.es/cima/dochtml/ft/85068/FT_85068.html	January 2024
Efluelda		New biological	Sanofi Pasteur		February 2021
ELZONRIS	tagraxofusp	New active substance and new biological, Authorised under exceptional circumstances	Stemline Therapeutics B.V.	https://www.ema.europa.eu/en/documents/product-information/elzonris-epar-product-information_en.pdf	January 2021
Enhertu	trastuzumab deruxtecan	New biological, new active substance, conditional marketing authorisation	Daiichi Sankyo Europe GmbH	https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf	January 2021
Enspryng Enoxaparin Becat (also known in some EU countries as Losima,	satralizumab Enoxaparin sodium	New active substance, new biological New biological	Roche Registration GmbH Laboartorios Farmacéuticos Rovi, S.A.	http://mri.cts-mrp.eu/Human/Product/Details/50005 <u>Not available</u>	July 2021 November 2018
ENOXAPARINE LEDRAXEN	enoxaparin sodium	New biological	VENIPHARM	https://www.ema.europa.eu/en/documents/product-information/enoxaparin-epar-product-information_en.pdf	September 2022
Enrylaze	Enisantaspase	New active substance, new biological	Jazz Pharmaceuticals Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/enrylaze-epar-product-information_en.pdf	September 2023
Enjaymo	Entimlimab	New active substance, new biological	Genzyme Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/enjaymo-epar-product-information_en.pdf	November 2022
Ervebo	Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live)	New active substance, new biological	Merck Sharp & Dohme B.V.	https://www.ema.europa.eu/en/documents/product-information/ervebo-epar-product-information_en.pdf	November 2019
Epysqli	Etulizumab	New biological	Samsung Bioepis NL B.V.	https://www.ema.europa.eu/en/documents/product-information/epysqli-epar-product-information_en.pdf	June 2023
Esperoct	Turoctocog alfa pegol	PASS ¹ New active substance, new biological,	Novo Nordisk A/S	https://www.ema.europa.eu/en/documents/product-information/esperoct-epar-product-information_en.pdf	June 2019
Evkeeza	evinacumab	PASS ¹ , authorised under exceptional circumstances	Ultragenyx Germany GmbH	https://www.ema.europa.eu/en/documents/product-information/evkeeza-epar-product-information_en.pdf	July 2021
Evrenzo	roxadustat	New active substance	Astellas Pharma Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/evrenzo-epar-product-information_en.pdf	September 2021
Evrysdi	risdiplam	New active substance	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/evrysdi-epar-product-information_en.pdf	April 2021
Evenity	Romosozumab	New active substance, new biological	UCB Pharma S.A.	https://www.ema.europa.eu/en/documents/product-information/evenity-epar-product-information_en.pdf	January 2020
Evoltra	Clofarabine	Authorised under exceptional circumstances	Genzyme Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/evoltra-epar-product-information_en.pdf	April 2013

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Evusheld	tixagevimab, cilgavimab	New active substance, new biological	☐ AstraZeneca AB	https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_en.pdf	March 2022
Exblifep	cefepime / enmetazobactam	New active substance	ADVANZ PHARMA Limited	https://www.ema.europa.eu/en/documents/product-information/exblifep-epar-product-information_en.pdf	April 2024
Exjade	Deferasirox	PASS ¹	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/exjade-epar-product-information_en.pdf	April 2013
Fabhalta	iptacopan	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf	May 2024
Fetcroja	Cefiderocol	New active substance	Shionogi B.V.	https://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf	May 2020
Filspari	Sparsentan	New active substance, Conditional marketing authorisation	Vifor France S.A.	https://www.ema.europa.eu/en/documents/product-information/filspari-epar-product-information_en.pdf	May 2024
Fintepla	fenfluramine	PASS ¹	UCB Pharma S.A.	https://www.ema.europa.eu/en/documents/product-information/fintepla-epar-product-information_en.pdf	January 2021
Firdapse	Amifampridine	Authorised under exceptional circumstances	BioMarin Europe Ltd	https://www.ema.europa.eu/en/documents/product-information/firdapse-epar-product-information_en.pdf	April 2013
Fluad Tetra	Influenza vaccine (surface antigen, inactivated, adjuvanted)	New biological	Seqirus Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/fluad-tetra-epar-product-information_en.pdf	June 2020
FRUZAQLA	fruquintinib	New active substance	Takeda Pharmaceuticals International AG Ireland Branch	https://www.ema.europa.eu/en/documents/product-information/fruzaqla-epar-product-information_en.pdf	July 2024
Gavreto	Pralsetinib	New active substance and under conditional marketing authorisation	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf	November 2021
Giapreza	Angiotensin II acetate	New active substance	PAION Deutschland GmbH	https://www.ema.europa.eu/en/documents/product-information/giapreza-epar-product-information_en.pdf	September 2019
Givlaari	Givosiran	New active substance	Alnylam Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/givlaari-epar-product-information_en.pdf	March 2020
Gonasi Set	Chorionic gonadotrophin	New biological	IBSA Farmaceutici Italia S.r.l.	https://www.ema.europa.eu/en/documents/product-information/gonasi-set-epar-product-information_en.pdf	May 2024
Hemgenix	etranacogene dezaparvovec	New biological, new active substance and Conditional Marketing Authorisation, PASS ¹	CSL Behring GmbH	https://www.ema.europa.eu/en/documents/product-information/hemgenix-epar-product-information_en.pdf	March 2023
Hepaxane	Enoxaparin sodium	New biological	Chemi S.P.A	https://www.ema.europa.eu/en/documents/product-information/hepaxane-epar-product-information_en.pdf	November 2018
Hepcludex	bulevirtide	new active substance	Gilead Sciences Ireland UC	https://www.ema.europa.eu/en/documents/assessment-report/heplisav-b-epar-public-assessment-report_en.pdf	August 2020
Heplisav B	hepatitis B surface antigen	New biological	Dynavax GmbH	https://www.ema.europa.eu/en/documents/product-information/heplisav-b-epar-product-information_en.pdf	March 2021
Herwenda	trastuzumab	New biological	Sandoz GmbH	https://www.ema.europa.eu/en/documents/product-information/herwenda-epar-product-information_en.pdf	November 2023
Holoclar	Ex vivo expanded autologous human corneal epithelial cells containing stem cells	Conditional marketing authorisation	Holostem S.r.l.	https://www.ema.europa.eu/en/documents/product-information/holoclar-epar-product-information_en.pdf	March 2015

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
JCOVDEN	COVID-19 vaccine (Ad26.COV2-S [recombinant])	New active substance, new biological	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf	Mar/21
JEMPERLI	dostarlimab	New active substance, new biological	GlaxoSmithKline (Ireland) Limited	https://www.ema.europa.eu/en/medicines/human/EPAR/jeraygo#product-info	May 2021
JERAYGO	aprocitentan	New active substance, PASS ¹	Idorsia Pharmaceuticals Deutschland GmbH	https://www.ema.europa.eu/en/documents/product-information/jinarc-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/jubbonti-epar-product-information_en.pdf	July 2024
Jinarc	Tolvaptan	PASS ¹	Otsuka Pharmaceutical Europe Ltd.	https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/kaftrio-epar-product-information_en.pdf	June 2015
Jubbonti	Īenosumab	New biological	Sandoz GmbH	https://www.ema.europa.eu/en/documents/product-information/kanuma-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/kapruvia-epar-product-information_en.pdf	May 2024
Jyseleca	filgotinib	New active substance	Galapagos NV	https://www.ema.europa.eu/en/documents/product-information/kauliv-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_en.pdf	October 2020
Kaftrio	ivacaftor / tezacaftor / elexi:	New active substance	Vertex Pharmaceuticals (Ireland) Limited	https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/ketoconazole-hra-epar-product-information_en.pdf	August 2020
Kanuma	Sebelipase alfa	PASS ¹	Alexion Europe SAS	https://www.ema.europa.eu/en/documents/product-information/kinpeygo-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/kimmtrak-epar-product-information_en.pdf	September 2015
Kapruvia	difelikefalin	New active substance	Vifor Fresenius Medical Care Renal Pharma France	https://www.ema.europa.eu/en/documents/product-information/kirsty-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/klisyri-epar-product-information_en.pdf	May/22
Kauliv	teriparatide	New biological	Strides Pharma (Cyprus) Ltd.	https://www.ema.europa.eu/en/documents/product-information/koselugo-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf	February 2023
Kerendia	finerenone	New active substance	Bayer AG	https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf	March 2022
Kesimpta	ofatumumab	New biological	Novartis Ireland Limited		April 2021
Ketoconazole HRA	Ketoconazole	PASS ¹	ERA Pharma Rare Diseases		December 2014
Kinpeygo	budesonide	Conditional marketing authorisation	STADA Arzneimittel AG		July 2022
KIMMTRAK	tebentafusp	New active substance and <i>new biological</i>	Immunocore Ireland Limited		Apr/22
Kirsty	Insulin aspart	New biological	Mylan IRE Healthcare Limited		February 2021
Klisyri	Tirbanibulin	New active substance, PASS ¹	Almirall, S.A.		July 2021
Koselugo	selumetinib	New active substance, conditional marketing authorisation, PASS ¹	AstraZeneca AB		June 2021
Kymriah	Tisagenlecleucel	PASS ¹	Novartis Europharm Limited		September 2018
Krazati	Īdagrasib	New active substance, Conditional Marketing Authorisation	Bristol Myers Squibb Pharma EEIG		January 2024

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Lamzede	Velmanase alfa Umeclidinium bromide/vilanterol trifenatate	authorised under exceptional circumstances	Chiesi Farmaceutici S.p.A.	https://www.ema.europa.eu/en/documents/product-information/lamzede-epar-product-information_en.pdf	April 2018
Laventair Ellipta		PASS ¹	Glaxo Group Ltd	https://www.ema.europa.eu/en/documents/product-information/laventair-ellipta-epar-product-information_en.pdf	June 2014
Ledraxen	Enoxaparin sodium	New biological	Venipharm	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?mpdidentifier=2196232	February 2019
Lemtrada	Alemtuzumab	PASS ¹	Sanofi Belgium	https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en.pdf	January 2020
Leqvio	inclisiran autologous CD34+ cell enriched population that contains hematopoietic	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_en.pdf	Jan/21
Libmeldy		New active substance and new biological, PASS ¹	Orchard Therapeutics (Netherlands) B.V.	https://www.ema.europa.eu/en/documents/product-information/libmeldy-epar-product-information_en.pdf	Jan/21
LIBTAYO	Cemiplimab	New active substance, new biological	Regeneron Ireland U.C.	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?directdisplay=true&mpdidentifier=2196936	July 2019
LiMAXetin 4 mg/ml Injektionslösung	Methacetin	New active substance	Humedics GmbH	https://www.ema.europa.eu/en/documents/product-information/libmyris-epar-product-information_en.pdf	May 2020
Libmyris	Adalimumab	New biological	STADA Arzneimittel AG	https://www.ema.europa.eu/en/documents/product-information/libmyris-epar-product-information_en.pdf	November 2021
Litfulo	ritlecitinib	New active substance	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/litfulo-epar-product-information_en.pdf	September 2023
Liumjev	Insulin lispro	New biological	Eli Lilly Nederland B.V.	https://www.ema.europa.eu/en/documents/product-information/lyumjev-previously-liumjev-epar-product-information_en.pdf	April 2020
Livmarli	maralixibat chloride	New active substance, Authorised under exceptional circumstances	Mirum Pharmaceuticals International B.V.	https://www.ema.europa.eu/en/documents/product-information/livmarli-epar-product-information_en.pdf	January 2023
Livogiva	teriparatide	New biological	Theramex Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/livogiva-epar-product-information_en.pdf	Aug/20
LIVTENCITY	maribavir	New active substance	Takeda Pharmaceuticals International AG Ireland Branch	https://www.ema.europa.eu/en/documents/product-information/livtencity-epar-product-information_en.pdf	November 2022
Loargys	pegzilarginase	New active substance, New biological, PASS ¹	Inmedica Pharma AB	https://www.ema.europa.eu/en/documents/product-information/loargys-epar-product-information_en.pdf	January 2024
Locametz	gozetotide	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/locametz-epar-product-information_en.pdf	January 2023
Lojuxta	Lomitapide	Authorised under exceptional circumstances	Amryt Pharmaceuticals DAC Ascendis Pharma Endocrinology Division A/S	https://www.ema.europa.eu/en/documents/product-information/lojuxta-epar-product-information_en.pdf	September 2013
Lonapegsomatropin Ascenc	Lonapegsomatropin	New active substance and new biological		https://www.ema.europa.eu/en/documents/product-information/lonapegsomatropin-ascendis-pharma-epar-product-information_en.pdf	January 2022
Lorviqua	Lorlatinib	New active substance and conditional marketing authorisation	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf	May 2019
LUMYKRAS	sotorasib	New active substance, Conditional marketing authorisation	Amgen Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf	January 2022

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Lunsumio	mosunetuzumab	New active substance, new biological and conditional marketing authorisation	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf	June 2022
Lupkynis	voclosporin	New active substance	Otsuka Pharmaceutical Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/lupkynis-epar-product-information_en.pdf	September 2022
Luxturna	Voretigene neparvovec	PASS ¹	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/luxturna-epar-product-information_en.pdf	December 2018
Lydisilka	drospirenone/estetrol	New active substance	Estetra SRL	https://www.ema.europa.eu/en/documents/product-information/lydisilka-epar-product-information_en.pdf	June 2021
Lyfnua	lirafapixant	New active substance	Merck Sharp & Dohme B.V.	https://www.ema.europa.eu/en/documents/product-information/lyfnua-epar-product-information_en.pdf	September 2023
Lytenava	bevacizumab gamma	New biological	Outlook Therapeutics Limited	https://www.ema.europa.eu/en/documents/product-information/lytenava-epar-product-information_en.pdf	June 2024
Lytgobi	futibatinib	New active substance, Conditional marketing authorisation	Taiho Pharma Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf	July 2023
Mayzent	Siponimod	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf	January 2020
Medikinet retard 10 / 20 / 30 / 40 / 5 / 50 / 60 mg	Methylphenidate hydrochloride	PASS ¹	Medice Arzneimittel Püttner GmbH Co. KG	Not available	May 2018
MenQuadfi	Meningococcal group A, C, W and Y conjugate vaccine	New biological	Sanofi Pasteur	https://www.ema.europa.eu/en/documents/product-information/menquadfi-epar-product-information_en.pdf	December 2020
Mepsevii	Vestronidase alfa	Authorized under exceptional circumstances	Ultragenyx Germany GmbH	https://www.ema.europa.eu/en/documents/product-information/mepsevii-epar-product-information_en.pdf	September 2018
Minjuvi	Tafasitamab	New active substance, new biological and conditional marketing authorisation	Incyte Biosciences Distribution B.V.	https://www.ema.europa.eu/en/documents/product-information/minjuvi-epar-product-information_en.pdf	September 2021
Mounjaro	tirzepatide	New active substance	Eli Lilly Nederland B.V.	https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf	September 2022
Mvabea	Ebola vaccine (MVA-BN-Filo [recombinant])	New active substance, new biological, authorised under exceptional circumstances	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/mvabea-epar-product-information_en.pdf	July 2020
Myalepta	Metreleptin	Authorized under exceptional circumstances	Amryt Pharmaceuticals DAC	https://www.ema.europa.eu/en/documents/product-information/myalepta-epar-product-information_en.pdf	September 2018
Mysimba	Naltrexone / bupropion	PASS ¹	Orexigen Therapeutics Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/mysimba-epar-product-information_en.pdf	April 2015
NADROPARINE CALCIQUE ASPEN	nadroparin calcium	New biological	ASPEN PHARMA TRADING LIMITED	Not available	September 2022
Natpar	Parathyroid hormone	Conditional authorisation	Shire Pharmaceuticals Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/natpar-epar-product-information_en.pdf	May 2017
Nepexto	Etanercept	New biological	Biosimilar Collaborations Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/nepexto-epar-product-information_en.pdf	June 2020
NEXPOVIO	selinexor	New active substance	Karyopharm Europe GmbH	https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf	April 2021

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Nexviadyme	avalglucosidase alfa	New active substance and new biological	Genzyme Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/nexviadyme-epar-product-information_en.pdf	July 2022
Ngenla	somatrogon	New active substance and new biological	□ Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/ngenla-epar-product-information_en.pdf	February 2022
Nilemdo	bempedoic acid	New active substance	Daiichi Sankyo Europe GmbH	https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf	April 2020
NUBEQA	darolutamide	New active substance	Bayer AG	https://www.ema.europa.eu/en/documents/product-information/nubeqa-epar-product-information_en.pdf	April 2020
NULIBRY	fosdenopterin	New active substance, authorised under exceptional circumstances	MC Pharma (EU) Limited	https://www.ema.europa.eu/en/documents/product-information/nulibry-epar-product-information_en.pdf	September 2022
Nustendi	bempedoic acid / ezetimibe	New active substance	Daiichi Sankyo Europe GmbH	https://www.ema.europa.eu/en/documents/product-information/nustendi-epar-product-information_en.pdf	April 2020
Nuvaxovid	SARS-CoV-2 recombinant spike protein	New active substance and new biological	Novavax CZ, a.s	https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf	January 2022
Nyvepria	pegfilgrastim	New biological New active substance, new biological, authorised under exceptional circumstances	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/nyvepria-epar-product-information_en.pdf	December 2020
NYXTHRACIS	obiltoxaximab	Authorised under exceptional circumstances	SFL Pharmaceuticals Deutschland GmbH	https://www.ema.europa.eu/en/documents/product-information/obiltoxaximab-sfl-epar-product-information_en.pdf	December 2020
Obizur	Susoctocog alfa	Authorised under exceptional circumstances	Baxalta Innovations GmbH	https://www.ema.europa.eu/en/documents/product-information/obizur-epar-product-information_en.pdf	November 2015
Obgemsa	Vibegron	New active substance	PIERRE FABRE MEDICAMENT	https://www.ema.europa.eu/en/documents/product-information/obgemsa-epar-product-information_en.pdf	July 2024
Ocaliva	Obeticholic acid	Conditional authorisation	ADVANZ PHARMA Limited	https://www.ema.europa.eu/en/documents/product-information/ocaliva-epar-product-information_en.pdf	January 2017
Ondexxya	Andexanet alfa	New active substance, new biological and conditional marketing authorisation	AstraZeneca AB	https://www.ema.europa.eu/en/documents/product-information/ondexxya-epar-product-information_en.pdf	May 2019
Ontozry	cenobamate	New active substance	Angelini Pharma S.p.A	https://www.ema.europa.eu/en/documents/product-information/ontozry-epar-product-information_en.pdf	April 2021
Omjjara	momelotinib	New active substance	GlaxoSmithKline Trading Services Limited	https://www.ema.europa.eu/en/documents/product-information/omjjara-epar-product-information_en.pdf	February 2024
Omlyclo	Omalizumab	New biological	Celltrion Healthcare Hungary Kft.	https://www.ema.europa.eu/en/documents/product-information/omlyclo-epar-product-information_en.pdf	June 2024
OmvoH	mirikizumab	New active substance, new biological	Eli Lilly Nederland B.V.	https://www.ema.europa.eu/en/documents/product-information/omvoh-epar-product-information_en.pdf	June 2023
Opdualag	nivolumab/relatlimab	New active substance, new biological	Bristol Myers Squibb Pharma EEIG	https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf	September 2022
Orladeyo	berotralstat	New active substance	Biocryst Ireland Limited	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?mpdidentifier=7000377	May 2021
Orylmyte	Allergen extract from house dust mites (Dermatophagoides)	New biological	Stallergenes		July 2021

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Orgovyx	relugolix	New active substance	Myovant Sciences Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/orgovyx-epar-product-information_en.pdf	May/22
Orphacol	Cholic acid	Authorised under exceptional circumstances	Laboratoires CTRS	https://www.ema.europa.eu/en/documents/product-information/orphacol-epar-product-information_en.pdf	October 2013
ORSERDU	elacestrant	New active substance	Stemline Therapeutics B.V.	https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf	September 2023
Oxbryta	Voxelotor	New active substance	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/oxbryta-epar-product-information_en.pdf	February 2022
Oyavas	bevacizumab	New biological	STADA Arzneimittel AG	https://cima.aemps.es/cima/dochtml/ft/82357/FichaTecnica_82357.html	April 2021
Ozanex (also known in some countries as Ozonoxacin)		New active substance	Ferrer Internacional S.A.	https://www.ema.europa.eu/en/documents/product-information/oxlumo-epar-product-information_en.pdf	November 2017
Oxlumo	lumasiran	New active substance	Alnylam Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/padcev-epar-product-information_en.pdf	December 2020
Padcev	enfortumab vedotin	New active substance and <i>new biological</i>	Astellas Pharma Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/palforzia-epar-product-information_en.pdf	April 2022
Palforzia	Defatted powder of Arachis	New biological	Immune Therapeutics Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/pandemic-influenza-vaccine-h5n1-astrazeneca-epar-product-information_en.pdf	November 2022
Pandemic influenza vaccine H5N1 AstraZeneca	Pandemic influenza vaccine (H5N1) (live attenuated, nasal)	Conditional marketing authorisation	AstraZeneca AB	https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf	June 2016
Paxlovid	ritonavir/ (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-	New active substance	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/pegfilgrastim-mundipharma-epar-product-information_en.pdf	February 2022
Pegfilgrastim Mundipharma	Pegfilgrastim	New biological	Mundipharma Biologics S.L.	https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf	January 2020
Pemazyre	pemigatinib	New active substance, conditional marketing authorisation	Incyte Biosciences Distribution B.V.	N/A	Apr/21
Percolozin	enoxaparin sodium	New biological	Venipharm	https://www.ema.europa.eu/en/documents/product-information/pesgo-epar-product-information_en.pdf	January 2022
Phesgo	pertuzumab / trastuzumab	New biological	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf	Jan/21
Piqray	Alpelisib	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf	August 2020
Pluvicto	lutetium (177Lu) vipivotide tetraxetan	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/polivy-epar-product-information_en.pdf	January 2023
Polivy	Polatuzumab vedotin	New active substance, new biological	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/ponvory-epar-product-information_en.pdf	January 2020
Ponvory	ponesimod	New active substance	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/pombiliti-epar-product-information_en.pdf	June 2021
Pombiliti	cipaglucosidase alfa	New active substance, new biological	Amicus Therapeutics Europe Limited		April 2023

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
PreHevbri	Hepatitis B vaccine (recombinant, adsorbed)	New biological	VBI Vaccines B.V.	https://www.ema.europa.eu/en/documents/product-information/prehevibri-epar-product-information_en.pdf	May/22
PyIclari	piflufolastat (18F)	New active substance	CURIUM PET France	https://www.ema.europa.eu/en/documents/product-information/pylclari-epar-product-information_en.pdf	September 2023
Pyrukynd	mitapivat	New active substance	Agios Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/pyrukynd-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/pyzchiva-epar-product-information_en.pdf	November 2022
Pyzchiva Dovprela (previously known as Pretomanid FGK)	ustekinumab	New biological	Samsung Bioepis NL B.V.	https://www.ema.europa.eu/en/documents/product-information/pretomanid-fgk-epar-product-information_en.pdf	May 2024
	pretomanid	New active substance	Mylan IRE Healthcare Limited	https://www.ema.europa.eu/en/documents/product-information/galsody-epar-product-information_en.pdf	August 2020
Qalsody Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta)	tofersen	New active substance, PASS ¹	Biogen Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en.pdf	June 2024
	Dinutuximab beta	Authorised under exceptional circumstances	EUSA Pharma (UK) Limited	https://www.ema.europa.eu/en/documents/product-information/qdenga-epar-product-information_en.pdf	May 2017
Qdenga	dengue tetravalent vaccine (live, attenuated)	New biological	Takeda GmbH	https://www.ema.europa.eu/en/documents/product-information/qinlock-epar-product-information_en.pdf	December 2022
QINLOCK	ripretinib	New active substance	Deciphera Pharmaceuticals (Netherlands) B.V.	https://www.ema.europa.eu/en/documents/product-information/quinsair-epar-product-information_en.pdf	Dec/21
Quinsair	Levofloxacin	PASS ¹	Chiesi Farmaceutici S.p.A.	https://www.ema.europa.eu/en/documents/product-information/quofenix-epar-product-information_en.pdf	April 2015
Quofenix	Delafloxacin	New active substance	Menarini - Industrie Farmaceutiche Riunite - s.r.l.	https://www.ema.europa.eu/en/documents/product-information/quviviq-epar-product-information_en.pdf	January 2020
QUVIVIQ	daridorexant	New active substance	Idorsia Pharmaceuticals Deutschland GmbH	https://www.ema.europa.eu/en/documents/product-information/ranivisio-epar-product-information_en.pdf	May 2022
Ranivisio	ranibizumab	New biological	Midas Pharma GmbH	https://www.ema.europa.eu/en/documents/product-information/raxone-epar-product-information_en.pdf	September 2022
Raxone	Idebenone	Authorised under exceptional circumstances	Chiesi Farmaceutici S.p.A.	https://www.ema.europa.eu/en/documents/product-information/rayvow-epar-product-information_en.pdf	September 2015
RAYVOW	lasmiditan	New active substance	Eli Lilly Nederland B.V.	https://www.ema.europa.eu/en/documents/product-information/reblozyl-epar-product-information_en.pdf	September 2022
Reblozyl	Luspatercept	New active substance	Celgene Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/recarbri-epar-product-information_en.pdf	July 2020
Recarbri	Imipenem / cilastatin / relebactam	New active substance	Merck Sharp & Dohme B.V.	https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf	February 2020
Refixia	Nonacog beta pegol	PASS ¹	Novo Nordisk A/S	https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf	June 2017
Regkirona	Regdanvimab	New active substance and <i>new biological</i>	Celltrion Healthcare Hungary Kft.	https://www.ema.europa.eu/en/documents/product-information/rekambys-epar-product-information_en.pdf	November 2021
REKAMBYS	rilpivirine	PASS ¹	Janssen-Cilag International NV		Jan/21

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Retsevmo	selpercatinib	New active substance, Conditional marketing authorisation	Eli Lilly Nederland B.V. ☐	https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf	February 2021
Revestive	Teduglutide	PASS ¹	Takeda Pharmaceuticals International AG Ireland Branch	https://www.ema.europa.eu/en/documents/product-information/revestive-epar-product-information_en.pdf	April 2013
Revlimid	Lenalidomide	PASS ¹	Bristol-Myers Squibb Pharma EEIG	https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf	June 2014
Rezzayo	Rezafungin	New active substance	Mundipharma GmbH	https://www.ema.europa.eu/en/documents/product-information/rezzayo-epar-product-information_en.pdf	January 2024
Rhokiinsa	Netarsudil	New active substance	Santen Oy	https://www.ema.europa.eu/en/documents/product-information/rhokiinsa-epar-product-information_en.pdf	December 2019
Rinvoq	Upadacitinib	New active substance	AbbVie Deutschland GmbH & Co. KG	https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf	January 2020
☐ Rimmyrah	Enibizumab	New biological	QUILU PHARMA SPAIN S.L.	https://www.ema.europa.eu/en/documents/product-information/rimmyrah-epar-product-information_en.pdf	January 2024
Roclanda	Latanoprost / netarsudil	New active substance New active substance, New biological, Conditional marketing authorisation and PASS ¹	Santen Oy	https://www.ema.europa.eu/en/documents/product-information/roclanda-epar-product-information_en.pdf	January 2021
Roctavian	valoctocogene roxaparvovec	PASS ¹	BioMarin International Limited	https://www.ema.europa.eu/en/documents/product-information/roctavian-epar-product-information_en.pdf	September 2022
Rolufta Ellipta (previously Fomeclidinium)		PASS ¹	GlaxoSmithKline Trading Services Limited	https://www.ema.europa.eu/en/documents/product-information/rolufta-ellipta-previously-rolufta-epar-product-information_en.pdf	March 2017
Ronapreve	Casirivimab/imdevimab	New active substance and <i>new biological</i>	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/ronapreve-epar-product-information_en.pdf	November 2021
Rozlytrek	entrectinib	New active substance, conditional MA	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf	August 2020
Rukobia	fostemsavir	New active substance	ViiV Healthcare BV	https://www.ema.europa.eu/en/documents/product-information/rukobia-epar-product-information_en.pdf	Feb/21
Ruxience	Rituximab	New biological	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus	April 2020
Rybelsus	Semaglutide	New biological	Novo Nordisk A/S	https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf	April 2020
Rybrevant	Amivantamab	Conditional marketing authorisation, new active substance, new biological	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/ryeqo-epar-product-information_en.pdf	January 2022
Ryeqo	relugolix / estradiol / norethisterone acetate	New active substance	Gedeon Richter Plc.	https://www.ema.europa.eu/en/documents/product-information/rystiggo-epar-product-information_en.pdf	September 2021
Rystiggo	Bzanolixizumab	New active substance, New biological	UCB Pharma S.A.	https://www.ema.europa.eu/en/documents/product-information/ryzneuta-epar-product-information_en.pdf	January 2024
Ryzneuta	efbemalenograstim alfa	New active substance and new biological	Evive Biotechnology Ireland LTD	https://www.ema.europa.eu/en/documents/product-information/saphnelo-epar-product-information_en.pdf	April 2024
Saphnelo	anifrolumab	New active substance and new biological	☐ AstraZeneca AB		February 2022

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Sarclisa	Isatuximab	New active substance and <i>new biological</i>	Sanofi Winthrop Industrie	https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf	June 2020
Scemblix	asciminib	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf	September 2022
Scenesse	Afamelanotide	Authorised under exceptional circumstances	Clinuvel UK Limited	https://www.ema.europa.eu/en/documents/product-information/scenesse-epar-product-information_en.pdf	January 2015
Sixmo	Buprenorphine	PASS ¹	L. Molteni & C. dei F.Ili Alitti Soc.Es.S.p.A	https://www.ema.europa.eu/en/documents/product-information/sixmo-epar-product-information_en.pdf	July 2019
Skyclarys	omaveloxolone	New active substance	Reata Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/skyclarys-epar-product-information_en.pdf	February 2024
Sogroya	somapacitan	New active substance and new biological	Novo Nordisk A/S	https://www.ema.europa.eu/en/documents/product-information/sogroya-epar-product-information_en.pdf	April 2021
Sondelbay	teriparatide	New biological	Accord Healthcare S.L.U.	https://www.ema.europa.eu/en/documents/product-information/sondelbay-epar-product-information_en.pdf	April 2022
SOTYKTU Spikevax (previously COVID-19 Vaccine Moderna)	deucravacitinib elasomeran (formally COVID-19 mRNA Vaccine (nucleoside-modified))	New active substance	Bristol Myers Squibb Pharma EEIG	https://www.ema.europa.eu/en/documents/product-information/sotyktu-epar-product-information_en.pdf	April 2023
		New active substance and new biological	MODERNA BIOTECH SPAIN, S.L.	https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf	Jan/21
Spravato	Esketamine	Restrictions with regards to the safe and effective use of the medicinal product	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf	January 2020
Stimufend	Pegfilgrastim	New biological	Fresenius Kabi Deutschland GmbH	https://www.ema.europa.eu/en/documents/product-information/stimufend-epar-product-information_en.pdf	April 2022
Strensiq	Asfotase alfa Autologous CD34+ enriched cell fraction that contains CD34+ cells	Authorised under exceptional circumstances	Alexion Europe SAS	https://www.ema.europa.eu/en/documents/product-information/strensiq-epar-product-information_en.pdf	September 2015
Strimvelis		PASS ¹	Fondazione Telethon ETS	https://www.ema.europa.eu/en/documents/product-information/strimvelis-epar-product-information_en.pdf	June 2016
Spevigo	Epresolimab	New active substance, new biological and Conditional marketing authorisation	Boehringer Ingelheim International GmbH	https://www.ema.europa.eu/en/documents/product-information/spevigo-epar-product-information_en.pdf	January 2023
Sublivac Birke	Allergen extract of pollen from Birch	New biological	HAL Allergie GmbH	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?accessid=amis_off_am_ppv&directdisplay=true&mpdid=entifier=2613841	September 2018
Sublivac Bäume	Allergen extract of pollen from Birch, Alder and Hazel	New biological	HAL Allergie GmbH	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?accessid=amis_off_am_ppv&directdisplay=true&mpdid=entifier=2613841	September 2018
Sunlenca	lenacapavir	New active substance	Gilead Sciences Ireland UC	https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-information_en.pdf	September 2022
				http://pub.rejestrymedyczne.csioz.gov.pl/ProduktSzczegoly.aspx?id=38063	
Sulovas	Sulodexide	New biological	Aflofarm Farmacja Polska Sp. z o.o.	https://www.ema.europa.eu/en/documents/product-information/sulovas-epar-product-information_en.pdf	December 2018
Sunosi	Solriamfetol quadrivalent influenza vaccine (recombinant, prepared in cell culture)	New active substance	Atrahs Pharma Netherlands B. V.	https://www.ema.europa.eu/en/documents/product-information/sunosi-epar-product-information_en.pdf	January 2020
Supemtek		New biological	Sanofi Pasteur	https://www.ema.europa.eu/en/documents/product-information/supemtek-epar-product-information_en.pdf	November 2020

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Sylvant	Siltuximab	PASS ¹	EUSA Pharma (Netherlands) B.V.	https://www.ema.europa.eu/en/documents/product-information/sylvant-epar-product-information_en.pdf	June 2014
Tabrecta	capmatinib	New active substance	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf	June 2022
TALVEY	talquetamab	New active substance, new biological and Conditional marketing authorisation	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/talvey-epar-product-information_en.pdf	September 2023
TAVLESSE	Fostamatinib	New active substance	Instituto Grifols S.A. □ Vifor Fresenius Medical Care Renal Pharma	https://www.ema.europa.eu/en/documents/product-information/tavlesse-epar-product-information_en.pdf	January 2020
Tavneos	avacopan	New active substance Conditional marketing authorisation /	France	https://www.ema.europa.eu/en/documents/product-information/tavneos-epar-product-information_en.pdf	January 2022
Tecartus	autologous anti-CD19-transduced CD3+ cells	New active substance and new biological/ PASS ¹	Kite Pharma EU B.V. □	https://www.ema.europa.eu/en/documents/product-information/tecartus-epar-product-information_en.pdf	Jan/21
Tecovirimat SIGA	tecovirimat monohydrate	Authorised under exceptional circumstances	SIGA Technologies Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/tecovirimat-siga-epar-product-information_en.pdf	January 2022
TECVAYLI	teclistamab	New active substance, new biological and	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf	September 2022
Temybrić Ellipta	Fluticasone furoate / umeclidinium / vilanterol	New active substance	GlaxoSmithKline Trading Services	https://www.ema.europa.eu/en/documents/product-information/temybric-ellipta-epar-product-information_en.pdf	July 2019
Tepkinly	epcoritamab	New active substance, new biological and conditional marketing authorisation	AbbVie Deutschland GmbH & Co. KG	https://www.ema.europa.eu/en/documents/product-information/tepkiny-epar-product-information_en.pdf	October 2023
□ Tepmetko	Tepotinib hydrochloride mo	New active substance	□ Merck Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf	March 2022
Tevimbra	tislelizumab	New biological	BeiGene Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf	September 2023
Tezspire	tezepelumab	New active substance and new biological	AstraZeneca AB	https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf	September 2022
Thiosix	Tioguanin	Authorised under exceptional circumstances	Teva Nederland B.V.	https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf http://db.cbg-meb.nl/IB-teksten/h114681.pdf	May 2015
Tibsovo	ivosidenib	New active substance	Les Laboratoires Servier	https://www.ema.europa.eu/en/documents/product-information/tizveni-epar-product-information_en.pdf	May 2023
Tizveni	Tislelizumab	New biological	BeiGene Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf	May 2024
Tofidence	tocilizumab	New biological	Biogen Netherlands B.V.	https://www.ema.europa.eu/en/documents/product-information/tofidence-epar-product-information_en.pdf	June 2024
Translarna	Ataluren	Conditional authorisation	PTC Therapeutics Limited	https://www.ema.europa.eu/en/documents/product-information/translarna-epar-product-information_en.pdf Not available	September 2014
Trivalent Influenza Vaccine	Influenza vaccine (split viric	New biological	Sanofi Pasteur	https://www.ema.europa.eu/en/documents/product-information/trodelyv-epar-product-information_en.pdf	May 2019
Trodelyv	sacituzumab govitecan	New active substance and new biological	Gilead Sciences Ireland UC		December 2021

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Truqap <u>Topiramate containing medicinal products in the European Union (For full</u>	capivasertib	New active substance	AstraZeneca AB	https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf	June 2024
	topiramate	PASS ¹	<u>Variuos (for full list see Annex XV)</u>	https://www.ema.europa.eu/en/medicines/human/referrals/topiramate	May 2024
TUKYSA	tucatinib	New active substance	Seagen B.V.	https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf	Feb/21
Tyenne	Ēcilizumab	New biological	Ēresenius Kabi Deutschland GmbH	https://www.ema.europa.eu/en/documents/product-information/tyenne-epar-product-information_en.pdf	September 2023
Tyruko	natalizumab	New biological	Sandoz GmbH	https://www.ema.europa.eu/en/documents/product-information/tyruko-epar-product-information_en.pdf	October 2023
Ultomiris	Ravulizumab	New active substance, new biological	Alexion Europe SAS	https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf	July 2019
Uplizna	inebilizumab	New active substance, new biological	Viela Bio B.V.	https://www.ema.europa.eu/en/documents/product-information/upstaza-epar-product-information_en-0.pdf	May 2022
Upstaza	Eladocagene exuparvovec	New active substance, new biological, authorised under exceptional circumstances	PTC Therapeutics International Limited	https://www.ema.europa.eu/en/documents/product-information/uzpruvo-epar-product-information_en.pdf	July 2022
Uzpruvo	ustekinumab	New biological	STADA Arzneimittel AG	https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf	January 2024
Vabysmo <u>Valproate and related substances (sodium valproate, valproic acid, valproate, valproic acid,</u>	Faricimab	New active substance, new biological	Ēbche Registration GmbH	https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances	September 2022
	Sodium valproate, valproic acid, valproate semisodium, valpromide	PASS ¹	<u>Various (For full list see Annex XIII)</u>	https://www.ema.europa.eu/en/documents/product-information/vafseo-epar-product-information_en.pdf	January 2015
Vafseo	Ēdadustat	New active substance	<u>ĀKEBIA EUROPE Limited</u>	https://www.ema.europa.eu/en/documents/product-information/vanflyta-epar-product-information_en.pdf	May 2023
VANFLYTA	quizartinib	New active substance	<u>Daiichi Sankyo Europe GmbH</u>	https://www.ema.europa.eu/en/documents/product-information/vaxchora-epar-product-information_en.pdf	November 2023
Vaxchora	Cholera vaccine (recombinant, live, oral)	New active substance, new biological	Bavarian Nordic A/S	https://www.ema.europa.eu/en/documents/product-information/vaxneuvance-epar-product-information_en.pdf	May 2020
Vaxneuvance Vaxigrip Tetra (also known in some EU countries as quadrivalent	pneumococcal polysaccharide	New active substance, new biological	Merck Sharp & Dohme B.V.	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?accessid=amis_off_am_ppv&directdisplay=true&mpdid	January 2022
	Influenza vaccine (split virion, inactivated)	New biological	Sanofi Pasteur Europe	https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf	January 2020
Vazkepa	Icosapent ethyl Tocofersolan d-alpha tocopheryl polyethylene glycol succinate	New active substance	Amarin Pharmaceuticals Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/vedrop-epar-product-information_en.pdf	Mar/21
Vedrop		Authorised under exceptional circumstances	Recordati Rare Diseases	https://www.ema.europa.eu/en/documents/product-information/vegzelma-epar-product-information_en.pdf	April 2013
VEGZELMA	bevacizumab	New biological	Celltrion Healthcare Hungary Kft.	https://www.ema.europa.eu/en/documents/product-information/veklury-epar-product-information_en.pdf	September 2022
Veklury	Remdesivir	New active substance	Gilead Sciences Ireland UC		July 2020

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Velsipity	etrasimod	New active substance	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/velsipity-epar-product-information_en.pdf	February 2024
Verquvo	Vericiguat	New active substance	Bayer AG	https://www.ema.europa.eu/en/documents/product-information/verquvo-epar-product-information_en.pdf	July 2021
Veozza	fāzolinetant	New active substance	Astellas Pharma Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/veozza-epar-product-information_en.pdf	January 2024
Vimizim	Elosulfase alfa	PASS ¹	BioMarin International Limited	https://www.ema.europa.eu/en/documents/product-information/vimizim-epar-product-information_en.pdf	June 2014
VITRAKVI	Larotrectinib	Conditional authorisation, new active substance	Bayer AG	https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf	October 2019
Vocabria	cabotegravir	New active substance, PASS ¹ Authorised under exceptional circumstances, new active substance and new biological	ViiV Healthcare BV	https://www.ema.europa.eu/en/documents/product-information/vocabria-epar-product-information_en.pdf	Jan/21
Voraxaze	glucarpidase		SERB SAS	https://www.ema.europa.eu/en/documents/product-information/voraxaze-epar-product-information_en.pdf	January 2022
Voxzogo	vosoritide	New active substance and new biological	BioMarin International Limited	https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf	Sep/21
Voydeya	danicopan	New active substance	Alexion Europe SAS	https://www.ema.europa.eu/en/documents/product-information/voydeya-epar-product-information_en.pdf	May 2024
Vueway	gadopiclenol	New active substance	Bracco Imaging SPA	https://www.ema.europa.eu/en/documents/product-information/vueway-epar-product-information_en.pdf	January 2024
Vydura	rimegepant	New active substance	Pfizer Europe MA EEIG	https://www.ema.europa.eu/en/documents/product-information/vydura-epar-product-information_en.pdf	May/22
Vyepti	eptinezumab	New biological	H. Lundbeck A/S	https://www.ema.europa.eu/en/documents/product-information/vyepti-epar-product-information_en.pdf	February 2022
Vyndaqel	Tafamidis	Authorised under exceptional circumstances	Pfizer Europa MA EEG	https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf	April 2013
Vyvgart	efgartigimod alfa	New active substance and new biological	argenx BV	https://www.ema.europa.eu/en/documents/product-information/vyvgart-epar-product-information_en.pdf	September 2022
Wakix	Pitolisant hydrochloride	PASS ¹	Bioprojet Pharma	https://www.ema.europa.eu/en/documents/product-information/wakix-epar-product-information_en.pdf	April 2016
Waylivra	Volanesorsen	New active substance and conditional marketing authorisation	Akcea Therapeutics Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/waylivra-epar-product-information_en.pdf	May 2019
Wegovy	semaglutide	New biological	Novo Nordisk A/S	https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf	January 2022
Wezenla	Ustekinumab	New biological	Amgen Technology (Ireland) UC	https://www.ema.europa.eu/en/documents/product-information/wezenla-epar-product-information_en.pdf	July 2024
Wyost	denosumab	New biological	Sandoz GmbH	https://www.ema.europa.eu/en/documents/product-information/wyost-epar-product-information_en.pdf	May 2024
Xembify	Human normal Immunoglobulin	New biological	Instituto Grifols S.A.	https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?accessid=amis_off_am_ppv&directdisplay=true&mpdid	March 2022

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
Xenleta	lefamulin	New active substance	Nabriva Therapeutics Ireland DAC	https://www.ema.europa.eu/en/documents/product-information/xenleta-epar-product-information_en.pdf	August 2020
Xenpozyme	olipudase alfa	New active substance, new biological	Genzyme Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/xenpozyme-epar-product-information_en.pdf	July 2022
Xevudy	Sotrovimab	New active substance, new biological	GlaxoSmithKline Trading Services Limited	https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdf	January 2022
Ximluci	Ēanibizumab	New biological	STADA Arzneimittel AG	https://www.ema.europa.eu/en/documents/product-information/ximluci-epar-product-information_en.pdf	November 2022
Xofigo	Radium Ra 223 dichloride	PASS ¹	Bayer AG	https://www.ema.europa.eu/en/documents/product-information/xofigo-epar-product-information_en.pdf	December 2013
Xofluza	baloxavir marboxil	New active substance	Roche Registration GmbH	https://www.ema.europa.eu/en/documents/product-information/xofluza-epar-product-information_en.pdf	January 2021
Xospata	Gilteritinib	New active substance	Astellas Pharma Europe B.V.	https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf	November 2019
Yesafili	aflibercept	New biological	Biosimilar Collaborations Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/yesafili-epar-product-information_en.pdf	September 2023
Yescarta	Axicabtagene ciloleucel	PASS ¹	Kite Pharma EU B.V.	https://portal.dimdi.de/amguifree/am/docoutput/jpadocdisplay.xhtml?globalDocId=E9C019E2F641455FBDB3AF3C8E60006F&directdisplay=true&docid=1	September 2018
Yimmugo	Human normal Immunoglobulin	New biological	Biotest Pharma GmbH	https://www.ema.europa.eu/en/documents/product-information/yorvipath-epar-product-information_en.pdf	November 2022
Yorvipath	palopegteriparatide	New active substance	Ascendis Pharma Bone Diseases A/S	https://www.ema.europa.eu/en/documents/product-information/yorvipath-epar-product-information_en.pdf	November 2023
Yselty	linzagolix choline	New active substance	Theramex Ireland Limited	https://www.ema.europa.eu/en/documents/product-information/yselty-epar-product-information_en.pdf	June 2022
Yuflyma	adalimumab	New biological	Celltrion Healthcare Hungary Kft.	https://www.ema.europa.eu/en/documents/product-information/yuflyma-epar-product-information_en.pdf	March 2021
Zabdeno	Ebola vaccine (Ad26.ZEBOV-GP [recombinant])	New active substance, new biological Authorised under exceptional circumstances	Janssen-Cilag International NV	https://www.ema.europa.eu/en/documents/product-information/zabdeno-epar-product-information_en.pdf	July 2020
Zegalogue	Dasiglucagon	New active substance	Zealand Pharma A/S	Not available yet	July 2024
Zeposia	Ozanimod	New active substance	Bristol-Myers Squibb Pharma EEIG	https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information_en.pdf	June 2020
Zercepac	trastuzumab	New Biological, New active substance	Accord Healthcare S.L.U.	https://www.ema.europa.eu/en/documents/product-information/zercepac-epar-product-information_en.pdf	August 2020
Zilbrysq	zilucoplan	New active substance	UCB Pharma S.A.	https://www.ema.europa.eu/en/documents/product-information/zilbrysq-epar-product-information_en.pdf	December 2023
Zokinvy	Lonafarnib	New active substance, authorised under exceptional circumstances	EigerBio Europe Limited	https://www.ema.europa.eu/en/documents/product-information/zokinvy-epar-product-information_en.pdf	July 2022
Zolgensma	Onasemnogene abeparvovec	New active substance, new biological	Novartis Europharm Limited	https://www.ema.europa.eu/en/documents/product-information/zolgensma-epar-product-information_en.pdf	May 2020
ZTALMY	Ēanaxolone	New active substance	Marinus Pharmaceuticals Emerald Limited	https://www.ema.europa.eu/en/documents/product-information/ztalmy-epar-product-information_en.pdf	September 2023
Zynlonta	loncastuximab tesirine	New active substance, new biological and Conditional marketing authorisation	ADC Therapeutics (NL) B.V.	https://www.ema.europa.eu/en/documents/product-information/zynlonta-epar-product-information_en.pdf	January 2023

Product name	Active substance (s)	Reason (s) on list	Marketing authorisation holder (s)	Link to product information	Date of inclusion
ZYNYZ	retifanlimab	New active substance, New biological	Īocyte Biosciences Distribution B.V.	https://www.ema.europa.eu/en/documents/product-information/zynyz-epar-product-information_en.pdf	May 2024

¹ PASS: Post-authorisation safety study. A PASS is defined in Article 1(15) of Directive 2001/83/EC as any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicinal product, or of measuring the effectiveness of risk management measures.

* This list was previously amended on 26 June 2024.

² Product currently suspended following a referral procedure under Article 20 of Regulation (EC) 726/2004.